{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166228121",
    "name" : "Annotation of CPIC Guideline for hydrocodone and CYP2D6",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1447983494,
        "name" : "CPIC® Guideline for Codeine and CYP2D6 – CPIC",
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
        "_url" : "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
        "version" : 1
      }
    ],
    "descriptiveVideoId" : "3qpg_keGm3s",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1451309842,
        "date" : "2021-01-12T00:00:00-08:00",
        "type" : "Create",
        "version" : 1
      },
      {
        "id" : 1451471004,
        "date" : "2021-07-14T10:15:47.491-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451598142,
        "date" : "2021-11-29T15:41:15.361-08:00",
        "description" : "Added video",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452137880,
        "date" : "2023-06-22T22:25:48.607-07:00",
        "description" : "Updated supplemental table links",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452465742,
        "date" : "2024-05-07T13:08:28.960-07:00",
        "description" : "Added link to hydrocodone CDS flowchart",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15115982,"title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249478","crossReferences":[{"id":1451837577,"resource":"PubMed Central","resourceId":"PMC8249478","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249478"},{"id":1451307240,"resource":"PubMed","resourceId":"33387367","_url":"https://www.ncbi.nlm.nih.gov/pubmed/33387367"},{"id":1451307241,"resource":"DOI","resourceId":"10.1002/cpt.2149","_url":"http://dx.doi.org/10.1002%2Fcpt.2149"}],"objCls":"Literature","pubDate":"2021-10-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : true,
    "recommendation" : true,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA449900",
        "name" : "hydrocodone",
        "version" : 11
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1451309840,
      "html" : "<p>CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.</p>\n<p>There is insufficient evidence to provide a dosing recommendation for hydrocodone in CYP2D6 ultrarapid metabolizers.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451433721,
      "html" : "<h3 id=\"december-2020\">December 2020</h3>\n<p>The authors of the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/\" target=\"_blank\">CPIC&reg; guideline for opioids and <em>CYP2D6</em>, <em>OPRM1</em> and <em>COMT</em></a> evaluated the available evidence for therapeutic dose recommendations for hydrocodone and <em>CYP2D6</em> metabolizer phenotypes.</p>\n<ul>\n<li>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>adult patients</li>\n<li>pediatric patients</li>\n</ul>\n</li>\n<li>\n<p>Excerpts from the guideline:</p>\n<ul>\n<li>&quot; For CYP2D6 ultrarapid metabolizers, there is insufficient evidence and confidence to\nprovide a recommendation to guide clinical practice at this time (no recommendation, CPIC level C).&quot;</li>\n<li>&quot;For CYP2D6 intermediate and poor metabolizers, there is some evidence to support decreased\nmetabolism of hydrocodone to the more active metabolite hydromorphone, but there is insufficient\nevidence to determine if these effects on pharmacokinetics translate into decreased analgesia or\nadverse events. Because of this, the use of hydrocodone label recommended age- or weight-specific dosing is recommended. However, if there is no response to hydrocodone in a CYP2D6 intermediate or poor metabolizer, the use of an alternative analgesic (non-opioid or opioid not affected by CYP2D6 phenotype) should be considered (optional recommendation, CPIC level B).&quot;</li>\n<li>&quot;It is not known if increasing the dose of hydrocodone would affect analgesia response in intermediate or poor metabolizers.&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367.pdf\" target=\"_blank\">CPIC&reg; Guideline for Opioids and <em>CYP2D6</em>, <em>OPRM1</em> and <em>COMT</em></a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367-supplement.pdf\" target=\"_blank\">2020 supplement</a></li>\n<li><a href=\"/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/drug_resource/hydrocodone-Drug_Resource_Mappings.xlsx\" target=\"_blank\">Hydrocodone Drug Resource Mappings</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/test_alert/hydrocodone_Pre_and_Post_Test_Alerts.xlsx\" target=\"_blank\">Hydrocodone Pre and Post Test Alerts</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/images/flow_chart/Hydrocodone_CDS_Flow_Chart.jpg\" target=\"_blank\">Hydrocodone Clinical Decision Support Flow Chart</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-hydrocodone-therapy-recommendations-based-on-cyp2d6-phenotype\">Table 1: Hydrocodone therapy recommendations based on CYP2D6 phenotype</h3>\n<p><em>Adapted from Tables 1 and 4 of the guideline.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype<sup>a</sup></th>\n<th>Activity score<br/>range</th>\n<th>Activity score<sup>b</sup></th>\n<th>Examples of<br/><em>CYP2D6</em> diplotypes<sup>b</sup></th>\n<th>Implications</th>\n<th>Recommendations</th>\n<th>Classification of<br/>recommendation<sup>d</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 ultrarapid metabolizer</td>\n<td>&gt;2.25</td>\n<td>&gt;2.25</td>\n<td><em>*1/*1xN, *1/*2xN, *2/*2xN<sup>c</sup></em></td>\n<td>Minimal evidence for pharmacokinetic or clinical effect.</td>\n<td>No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>CYP2D6 normal metabolizer</td>\n<td>1.25 &lt;= x &lt;= 2.25</td>\n<td>1.25<br/>1.5<br/>1.75<br/>2.0<br/>2.25</td>\n<td><em>*1/*10<br/>*1/*41, *1/*9<br/>*10/*41x3<br/>*1/*1, *1/*2<br/>*2x2/*10</em></td>\n<td>Normal hydromorphone formation</td>\n<td>Use hydrocodone label recommended age- or weight-specific dosing</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>CYP2D6 intermediate metabolizer</td>\n<td>0 &lt; x &lt; 1.25</td>\n<td>0.25<br/>0.5<br/>0.75<br/>1.0</td>\n<td>*4/*10<br/>*4/*41, *10/*10<br/>*10/*41<br/>*41/*41, *1/*5</td>\n<td>Minimal evidence for pharmacokinetic or clinical effect.</td>\n<td>Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid</td>\n<td>Optional</td>\n</tr>\n<tr>\n<td>CYP2D6 poor metabolizer</td>\n<td>0</td>\n<td>0</td>\n<td><em>*3/*4, *4/*4, *5/*5, *5/*6</em></td>\n<td>Decreased metabolism of hydrocodone to active metabolite hydromorphone, but there is insufficient evidence to determine if these effects on pharmacokinetics translate into decreased analgesia or side effects.</td>\n<td>Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid</td>\n<td>Optional</td>\n</tr>\n<tr>\n<td>CYP2D6 Indeterminate</td>\n<td>n/a</td>\n<td>An individual carrying one or two unknown or uncertain function alleles</td>\n<td><em>*1/*22, *1/*25, *22/*25</em></td>\n<td>n/a</td>\n<td>No recommendation</td>\n<td>No recommendation</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> See the <strong>CYP2D6 Frequency Table</strong> on the <a href=\"/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a> for biogeographical group-specific allele and phenotype frequencies.<br />\n<sup>b</sup> Assignment of allele function and allele activity values including citations for allele function can be found in the <strong>CYP2D6 Allele Definition Table</strong> and <strong>CYP2D6 Allele Functionality Table</strong>. For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the <strong>CYP2D6 Genotype to Phenotype Table</strong>. All of these tables can be accessed on the <a href=\"/page/cyp2d6RefMaterials\">CYP2D6 Gene-Specific Information Tables page</a>.<br />\n<sup>c</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental\ndata for additional information on how to translate diplotypes into phenotypes.<br />\n<sup>d</sup> Rating scheme described in the Strength of Recommendations section in the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367-supplement.pdf\" target=\"_blank\">guideline supplement</a></p>\n",
      "version" : 2
    },
    "version" : 7
  }
}